Manages well-differentiated thyroid cancer Thyroid Suppression Test. ANDA 214803, held by Zydus Lifesciences. Liothyronine Sodium.
As of Nov 21, 2026, ANDA 214803 (Liothyronine Sodium), held by Zydus Lifesciences, was first approved by FDA on Jan 22, 2021, with 0 approved supplements and 0 published complete response letters.
Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 22, 2021 | Original application | Approved | None posted |
| Liothyronine SodiumEQ 0.005MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.025MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.05MG BASE · tablet;oral | Liothyronine Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters